


DAFTAR PUSTAKA

1. Momenimovahed Z, Ghoncheh M, Pakzad R, Hasanpour H, Salehiniya H. Incidence and mortality of uterine cancer and relationship with human development index in the world. *Cukurova Med J.* 2017;42(2):233–40.
2. WHO. World Global Cancer Observatory. International Agency for Research on Cancer. 2020 (Diakses Maret 2021). Tersedia dari : <https://gco.iarc.fr/today/data/factsheets/populations/900-world-factsheets.pdf>.
3. American Cancer Society. Cancer facts and figures 2018. GA; American Cancer Society.2018(Diakses Agustus 2020). Tersedia dari : <https://www.cancer.org/content/dam/cancerorg/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf>.
4. WHO. Indonesia Global Cancer Observatory. International Agency for Research on Cancer. 2020 (Diakses Maret 2021). Tersedia dari : <https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-factsheets.pdf>
5. Rojas V, Hirshfield K. M, Ganesan S, Rodriguez-Rodriguez L. Molecular characterization of epithelial ovarian cancer: implications for diagnosis and treatment. *Int J Mol Sci.* 2016;17(12): 2113.
6. Berek, J. S., Hacker, N. F., Hengst, T. *Gynecologic Oncology Sixth Edition*.
7. Javadi S, Ganeshan DM, Qayyum A, Iyer RB, Bhosale P. Ovarian Cancer, the Revised FIGO Staging System, and the Role of Imaging. *AJR Am J Roentgenol.* 2016 Jun;206(6):1351-60.
8. Rambe IR, Asri A, Adrial A. Profil Tumor Ganas Ovarium di Laboratorium Patologi Anatomi Fakultas Kedokteran Universitas Andalas Periode Januari 2011 Sampai Desember 2012. *Jurnal Kesehatan Andalas.* 2014;3(1):54-7.
9. Setiati S, Alwi I, Sudoyo AW, Stiyohadi B, Syam AF. Buku ajar ilmu penyakit dalam jilid III. Edisi 6. Jakarta: InternaPublishing; 2017:3050.
10. Meys EMJ, Jeelof LS, Achtern NMJ, et al. Estimating risk of malignancy in adnexal masses: external validation of the ADNEX model and comparison with other frequently used ultrasound methods. *Ultrasound Obstet Gynecol.* 2017;49(6):784-92.
11. Jeong SY, Park BK, Lee YY, Kim T-J. Validation of IOTA-ADNEX Model in Discriminating Characteristics of Adnexal Masses: A Comparison with Subjective Assessment. *J Clin Med.* 2020;9(6):2010.

- 
12. Froyman W, Timmerman D. Methods of Assessing Ovarian Masses: International Ovarian Tumor Analysis Approach. *Obstet Gynecol Clin North Am.* 2019;46(4):625-41.
 13. Araujo KG, Jales RM, Pereira PN, et al. Performance of the IOTA ADNEX model in preoperative discrimination of adnexal masses in a gynecological oncology center. *Ultrasound Obstet Gynecol.* 2017;49(6):778-83.
 14. Van Calster B, Van Hoorde K, Valentin L, et al. Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: Prospective multicentre diagnostic study. *BMJ.* 2014;349:1-14
 15. Sayasneh A, Ferrara L, De Cock B, Saso S, Al-Memar M, Johnson S, Kaijser J, Carvalho J, Husicka R, Smith A, Stalder C, Blanco MC, Ettore G, Van Calster B, Timmerman D, Bourne T. Evaluating the risk of ovarian cancer before surgery using the ADNEX model: a multicentre external validation study. *Br J Cancer.* 2016 Aug 23;115(5):542-8.
 16. Viora E, Piovano E, Baima Poma C, Cotrino I, Castiglione A, Cavallero C, et al. The ADNEX model to triage adnexal masses: An external validation study and comparison with the IOTA two-step strategy and subjective assessment by an experienced ultrasound operator. *Eur J Obstet Gynecol Reprod Biol.* 2020;247:207-11.
 17. Hu J, Shi Y, Li M, Yi C. Clinical Performance of ADNEX (The Assessment of Different NEoplasias in the adneXa) Model in Early Diagnosis and Staging of Benign and Malignant Ovarian Tumors. *Yangtze Med.* 2017;01(03):148-56.
 18. Van Calster B, Van Hoorde K, Froyman W, et al. Practical guidance for applying the ADNEX model from the IOTA group to discriminate between different subtypes of adnexal tumors. *Facts, views Vis ObGyn.* 2015;7(1):32-41.
 19. Snell RS. Anatomi Klinis Berdasarkan Sistem. 2012.
 20. Junqueira. Basic Histology Text and Atlas 14th Edition. 2013.
 21. National Comprehensive Cancer Network. NCCN Guidelines for Patients. Ovarian Cancer - Epithelial Ovarian Cancer. Version 1.2019, March 8, 2019:8.
 22. Kurman RJ, Shih IM. The origin and pathogenesis of epithelial ovarian cancer: A proposed unifying theory. *Am J Surg Pathol.* 2010;34(3):433-43.
 23. Koshiyama M, Matsumura N, Konishi I. Recent concepts of ovarian carcinogenesis: type I and type II. *Biomed Res Int.* 2014;2014:934261.

24. Budiana ING, Angelina M, Pemayun TGA. Ovarian cancer: Pathogenesis and current recommendations for prophylactic surgery. *J Turkish-German Gynecol Assoc.* 2019;20(1):47-54.
25. Shisheboran MD, Genestie C. Pathobiology of Ovarian Carcinomas. *Chinese Journal of Cancer*. 2015;34(1):50-5.
26. WHO. Asia Global Cancer Observatory. International Agency for Research on Cancer. 2020 (Diakses Maret 2021). Tersedia dari : <https://gco.iarc.fr/today/data/factsheets/populations/935-asia-fact-sheets.pdf>.
27. Prat, J. Ovarian carcinomas : five distinct diseases with different origins , genetic alterations , and clinicopathological features. 237–249 (2012) doi:10.1007/s00428-012-1203-5.
28. McCluggage WG. Morphological Subtypes of Ovarian Carcinoma: A Review with Emphasis on New Developments and Pathogenesis. *Pathology*. 2011;43:420-32.
29. Aziz MF, Andrijono, Saifuddin AB. Onkologi Ginekologi. Diagnosis. 1st ed. Jakarta: PT Bina Pustaka Sarwono Prawirohardjo. 2006.p.200-4.
30. Arora N, Talhouk A, McAlpine JN, Law MR, Hanley GE. Long-term mortality among women with epithelial ovarian cancer: a population-based study in British Columbia, Canada. *BMC Cancer*. 2018 Oct 25;18(1):1039.
31. Zheng G, Yu H, Kanerva A, Försti A, Sundquist K, Hemminki K. Familial risks of ovarian cancer by age at diagnosis, proband type and histology. *PLoS One*. 2018 Oct 3;13(10):e0205000.
32. Ørskov M, Iachina M, Guldberg R, Mogensen O, Mertz Nørgård B. Predictors of mortality within 1 year after primary ovarian cancer surgery: a nationwide cohort study. *BMJ Open*. 2016 Apr 21;6(4):e010123.
33. Smith ER, Xu XX. Ovarian ageing, follicle depletion, and cancer: a hypothesis for the aetiology of epithelial ovarian cancer involving follicle depletion. *Lancet Oncol*. 2008;9(11):1108-11.
34. Momenimovahed Z, Tiznobaik A, Taheri S, Salehinya H. Ovarian cancer in the world : epidemiology and risk factors. Published online 2019:287-99.
35. Gaitskell, K., Green, J., Pirie, K., Barnes, I., Hermon, C., Reeves, G. K., & Million Women Study Collaborators. Histological subtypes of ovarian cancer associated with parity and breastfeeding in the prospective Million Women Study. *Int. J. Cancer*. 2018;142(2): 281-9.

36. Chiang A. J, Chang C, Huang C. H, Huang W. C, Kan Y. Y, Chen, J. Risk factors in progression from endometriosis to ovarian cancer: a cohort study based on medical insurance data. *Journal of gynecologic oncology*, 2018;29(3):28.
37. Reid, B. M., Permuth, J. B., & Sellers, T. A. Epidemiology of ovarian cancer: a review. *Cancer biology & medicine*.2017;14(1): 9.
38. J. Staples and A. Goodman, “PARP inhibitors in ovarian cancer,” in Ovarian Cancer—A Clinical and Translational Update, I. D’iaz-Padilla, Ed., chapter 14, InTech, 2013.
39. Giulia Girolimetti,¹ Anna Myriam Perrone,² Donatella Santini,³ Elena Barbieri,⁴ Flora Guerra,⁵ Simona Ferrari, *et al.* BRCA-Associated Ovarian Cancer: From Molecular Genetics to Risk Management. Hindawi.2014:1-11.
40. S. Banerjee and S. Kaye, “PARP inhibitors in BRCA genemutated ovarian cancer and beyond,” *Current Oncology Reports*, 2011;vol. 13, no. 6, pp. 442–9.
41. Nakamura K, Banno K, Yanokura, M, Iida, M, Adachi M, Masuda K, *et al.* Features of ovarian cancer in Lynch syndrome (Review). *Molecular and clinical oncology*, 2014;2(6), 909–16.
42. Helder-Woolderink JM, Blok EA, Vasen HF, Hollema H, Mourits MJ, De Bock GH. Ovarian cancer in Lynch syndrome; a systematic review. *Eur J Cancer*. 2016 Mar;55:65-73.
43. Fathalla MF. Incessant Ovulation and Ovarian Cancer. *Facts Views Vis Obgyn*. 2013; 5(4): 292–7.
44. Erickson, B. K., Conner, M. G., & Landen, C. N., Jr. The role of the fallopian tube in the origin of ovarian cancer. *American journal of obstetrics and gynecology*. 2013; 209(5), 409–14.
45. Doubeni, C. A., Doubeni, A. R. B. & Myers, A. E. Diagnosis and management of ovarian cancer. *Am. Fam. Physician*. 2016. **93**, 937–44.
46. Saida T, Tanaka YO, Matsumoto K, Satoh T, Yoshikawa H, Minami M. Revised FIGO Staging System for Cancer of The Ovary, Fallopian Tube, and Peritoneum: Important Implications for Radiologist. *Jpn J Radiol*. 2016;34(2):117-24.
47. Dhitayoni Ayu Ida BGNI. Profil Pasien Kanker Ovarium di Rumah Sakit Umum Pusat Sanglah Denpasar - Bali Periode Juli 2013 - Juni 2014. 2017;6(3):125-31.

48. Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019 Mar 23;393(10177):1240-53.
49. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018 Jul;68(4):284-96.
50. Boussios S, Zarkavelis G, Seraj E, Zerde I, Tatsi K, Pentheroudakis G. Non-epithelial Ovarian Cancer: Elucidating Uncommon Gynaecological Malignancies. Anticancer Res. 2016 Oct;36(10):5031-42.
51. Chien J, Poole EM. Ovarian Cancer Prevention, Screening, and Early Detection: Report From the 11th Biennial Ovarian Cancer Research Symposium. *Int J Gynecol Cancer*. 2017;27(9S Suppl 5):20-2.
52. Dahlan, M. S. *Statistik Untuk Kedokteran Dan Kesehatan*. Edisi 3. Salemba Medika, 2013.
53. Scholler N, Urban N, Gene CA. CA125 in ovarian cancer. 2010;1(4):513– 23.
54. Dwi ariningtyas N. CA 125 dan pemakaian klinis dalam penatalaksanaan kanker ovarium. Qanun Med - Med J Fac Med Muhammadiyah Surabaya. 2018;2(2):73–82.
55. Huy, N. V. Q. *et al*. Standard and optimal cut-off values of serum ca-125, HE4 and ROMA in preoperative prediction of ovarian cancer in Vietnam. *Gynecol. Oncol. Reports*. 2018;25, 110–4.